News

The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as

The phase III trial will compare daratumumab in combination with bortezomib, melphalan and prednisone to bortezomib, melphalan and prednisone alone as front line treatment for patients who are

This could result in a total of 34 medicines being sold through pharmacies without prescription. The list includes medicines for the treatment of migraine, acid-reflux symptoms, hay fever,

As part of the deal, Pfizer will make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments. The transaction, which is subject

The two-period Phase III trial consisted of six months of on-demand therapy only, followed by 12 months of routine prophylaxis with BeneFIX 100 IU/kg once-weekly. The open-label, non-randomized

The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy

The trial would evaluate the safety and efficacy of ViaCyte’s VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical

The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with

Top-line data from the trial, designated the ARM-TD (Aim to Reduce Movements in Tardive Dyskinesia) study, are expected in mid-2015. "Tardive dyskinesia is a side effect of certain